This one-day in-person workshop* is designed as a complement to the two-day Psychedelics 101 & 102 program. This event listing is intended for individuals who have previously attended 101 & 102. To register for the full three days please see this event listing. A limited number of tickets are available for the two-day 101 & 102 program only, as well. Please see this event listing for that option. We strongly encourage participants to take the full 3-day workshop if they have not previously attended 101 & 102.

*As of posting the intention is to offer this program in-person. In the event that public health policy does not allow us to offer it in person as of thirty-days prior to the event, it will be rescheduled for a later date—not moved to an online format.

Mindfulness meditation practices offer an opportunity to practice integration of all non-ordinary  states of consciousness, including psychedelic experiences. In this program, participants engage in a series of meditative experiences and integration techniques to cultivate an ongoing relationship with the profound insights of those states, also applicable to more ephemeral psychedelic experiences. Attendees will gain an understanding of how contemplative and mind-body practices can support patients in touching into and gently staying with experiences and insights of psychedelic experiences so that these might be further incorporated into the larger scope of life. The content and practice of mindfulness for psychedelic integration will be explored in a supportive, experiential space that allows participants to give voice to their own experience with non-verbal, inner directed guidance.

Instructors


Elizabeth Nielson, Ph.D.

Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.

Ingmar Gorman, Ph.D.

Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.